Long-term outcomes in pulmonary arterial hypertension

被引：3
|
作者：
Thenappan, T. [1 ]
Palevsky, H. I. [2 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Med, Cardiol Sect, Chicago, IL 60637 USA
[2] Univ Penn Hlth Syst, Penn Presbyterian Med Ctr, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA USA
来源：
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2009年 / 63卷
关键词：
INTRAVENOUS EPOPROSTENOL; SURVIVAL; THERAPY; REGISTRY; ANTICOAGULANT; METAANALYSIS; BOSENTAN; TRIALS;
D O I：
10.1111/j.1742-1241.2009.02128.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：42 / 44
页数：3
相关论文
共 50 条
  • [31] From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension
    Chakinala, Murali M.
    Barst, Robyn
    PULMONARY CIRCULATION, 2013, 3 (03) : 507 - 522
  • [32] Long-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension
    Rich, Stuart
    Pogoriler, Jennifer
    Husain, Aliya N.
    Toth, Peter T.
    Gomberg-Maitland, Mardi
    Archer, Stephen L.
    CHEST, 2010, 138 (05) : 1234 - 1239
  • [33] Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS)
    Kolstad, Kathleen D.
    Li, Shufeng
    Steen, Virginia
    Chung, Lorinda
    CHEST, 2018, 154 (04) : 862 - 871
  • [34] Long-Term Outcomes in Idiopathic Pulmonary Arterial Hypertension (iPAH) Treated in the Netherlands, 1998-2007
    Jacobs, W.
    Brand, M.
    Rosenberg, D. M.
    Schaaf, B.
    Boonstra, A.
    Noordegraaf, A. Vonk
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] Impact of Initial Therapeutic Strategy on Long-Term Outcomes in Pulmonary Arterial Hypertension: An Analysis of the PHSANZ Registry
    Kearney, K.
    Lavender, M.
    Cordina, R.
    Collins, N.
    Corrigan, C.
    Dwyer, N.
    Feenstra, J.
    Keating, D.
    McWilliams, T.
    Williams, T.
    Whitford, H.
    Wrobel, J.
    Keogh, A.
    Kotlyar, E.
    Lau., E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S27 - S28
  • [36] Impact of initial therapeutic strategy on long-term outcomes in pulmonary arterial hypertension: An analysis of the PHSANZ registry
    Kearney, K.
    Lavender, M.
    Cordina, R.
    Collins, N.
    Corrigan, C.
    Dwyer, N.
    Feenstra, J.
    Keating, D.
    McWilliams, T.
    Williams, T.
    Whitford, H.
    Whyte, K.
    Weintraub, R.
    Wrobel, J.
    Keogh, A.
    Kotlyar, E.
    Lau, E.
    RESPIROLOGY, 2022, 27 : 50 - 50
  • [37] LONG-TERM OUTCOMES OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND CONNECTIVE TISSUE DISEASE TREATED WITH INTRAVENOUS EPOPROSTENOL
    Shirai, Y.
    Yasuoka, H.
    Takeuchi, T.
    Satoh, T.
    Kuwana, M.
    RHEUMATOLOGY, 2012, 51 : 60 - 61
  • [38] Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
    Weatherald, Jason
    Chaumais, Marie-Camille
    Savale, Laurent
    Jais, Xavier
    Seferian, Andrei
    Canuet, Matthieu
    Bouvaist, Helene
    Magro, Pascal
    Bergeron, Anne
    Guignabert, Christophe
    Sitbon, Olivier
    Simonneau, Gerald
    Humbert, Marc
    Montani, David
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (01)
  • [39] Long-term inhaled iloprost use in children with pulmonary arterial hypertension
    Alehan, Dursun
    Yildirim, Isil
    Sahin, Murat
    Ozkutlu, Suheyla
    Ozer, Sema
    Karagoz, Tevfik
    CARDIOLOGY IN THE YOUNG, 2012, 22 (04) : 396 - 403
  • [40] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Calcaianu, Mihaela
    Canuet, Matthieu
    Enache, Irina
    Kessler, Romain
    PULMONARY CIRCULATION, 2017, 7 (02) : 439 - 447
12345